COVID-19 Vaccines In Children Under Five Get CDC Backing As Panel Worries FDA Didn’t Go Far Enough
Executive Summary
Calling Moderna’s and Pfizer’s vaccines ‘options’ for young children downplays the risks to the population, some CDC advisory committee members argue as they urge a strong message for vaccination given the more than 200 COVID-19 deaths in children six months to five years.
You may also be interested in...
Coronavirus Update: Pfizer/BioNTech Announce Positive Early Booster Data
The announcement comes amid signs of lagging bivalent booster uptake despite the possibility of a fall and winter surge. Novavax announced data from its combination coronavirus-influenza vaccine, but doubts remain as its approach’s competitiveness against mRNA vaccines. Moderna and Pfizer received EUAs for their bivalent vaccines in young children.
COVID-19 Vaccine Dosing Interval Studies Advocated By US FDA, ACIP
FDA’s Doran Fink and CDC’s ACIP members say vaccine manufacturers could conduct a study to determine whether longer intervals between doses would provide greater effectiveness and longer durability. Right now, they are relying on international data.
Moderna, Pfizer Nab Unanimous Votes For Pediatric COVID Vaccines But Advisors Hint At Moderna Dosing Advantage
US FDA advisory committee members raised some concerns regarding Pfizer’s three-dose schedule for children under five, suggesting Moderna’s two-dose primary series may be preferred.